# Research Peptide Fundamentals: How Research Peptides Get Their Names > mybiopeptides — Research Peptide Fundamentals: How Research Peptides Get Their Names — Research Peptide Fundamentals, read through the labels: an independent literature digest on how research peptides are named — generic names, company codes, lab acronyms and nicknames — worked through semaglutide, tirzepatide, CJC-1295, BPC-157 and PT-141. **RESEARCH PEPTIDE FUNDAMENTALS** Five of the most-studied peptides in the literature, each one a worked example of a different naming system — and of how much a reader can infer from a label before reading a single study. ### [Semaglutide](/semaglutide) ![Semaglutide research illustration](images/semaglutide.webp) The generic-name case. One molecule, three company codes before it was ever called semaglutide, and three trademarks after — Ozempic, Wegovy and Rybelsus — while the ending -glutide quietly announces its receptor family. ### [Tirzepatide](/tirzepatide) ![Tirzepatide research illustration](images/tirzepatide.webp) The case of the stem that is missing. It ends in -tide like every peptide here, but pointedly not in -glutide — and the difference tracks a real difference in what the molecule binds. ### [CJC-1295](/cjc-1295) ![CJC-1295 research illustration](images/cjc-1295.webp) The company-code case, and the cautionary one. Two forms circulate under names that look almost identical — DAC and no-DAC — while behaving completely differently in the body. ### [BPC-157](/bpc-157) ![BPC-157 research illustration](images/bpc-157.webp) The descriptive-acronym case. BPC unpacks to Body Protection Compound, a name chosen by the lab that described it — and one that makes a claim the evidence has not yet earned. ### [PT-141](/pt-141) ![PT-141 research illustration](images/pt-141.webp) The one-molecule-three-names case. PT-141, bremelanotide and Vyleesi are the same compound — but the name in use signals which supply chain, and which regulatory status, is being discussed. ## The short version Every peptide on this site answers to more than one name. Semaglutide has also been called NNC0113-0217, and reaches pharmacy shelves under three separate trademarks: Ozempic, Wegovy and Rybelsus. BPC-157 is also Body Protection Compound 157, and also PL 14736. PT-141, bremelanotide and Vyleesi are one molecule with three labels. None of this is trivia. Each name comes from a different system, and each system was built to answer a different question. A **peptide** is a short chain of amino acids — the same building blocks proteins are made from, just far fewer of them strung together. Researchers build synthetic ones to copy, extend, or block a signal the body already uses. This site takes five of the most-studied research peptides and treats each as a worked example of one naming convention: the official generic name, the drug-company development code, the descriptive laboratory acronym, the chemistry-derived label, and the nickname that spreads through forums. Working out which kind of name is on the vial is the fastest way to tell what sort of thing is being described — and how much evidence is standing behind it. ## Five molecules, five naming systems Peptide names are not assigned by one authority working from one rulebook. They accumulate. A molecule typically picks up a company code first, while it is still a program rather than a product; it may acquire a descriptive nickname from the lab that characterised it; if it advances far enough through regulatory review it is assigned an **International Nonproprietary Name**, the generic name intended for use worldwide; and if it reaches market it is also sold under one or more trademarks owned by its manufacturer. Some molecules collect all four. Some stall after the first and keep their code forever. Semaglutide is the fullest specimen of that sequence, and the clearest demonstration that the last register multiplies where the others do not. One molecule, one generic name — and three trademarks, **Ozempic**, **Wegovy** and **Rybelsus**, because a trademark names a marketed product rather than a compound. That sequence is why the naming register is informative on its own. A name like **LY3298176** or **NNC0113-0217** is a company development code — letters identifying the originating organisation, digits identifying the compound within it. A name like **BPC-157** is a laboratory acronym, coined to describe what the researchers thought the molecule did. A name like **semaglutide** is a generic name, which means a standards body reviewed and assigned it. A phrase like *GLP-1 receptor agonist* is not a name at all — it is a class descriptor, naming a target rather than a molecule. The five compounds here were chosen because between them they demonstrate every one of those registers, and because the boundaries between the registers turn out to carry real consequences. The clearest of those consequences is documented on the CJC-1295 page, where two circulating forms of one compound are routinely conflated under near-identical names despite behaving very differently in the body. ## What "research peptide" actually covers The phrase *research peptide* is used loosely enough to hide an enormous regulatory gap, and the five compounds here sit on opposite sides of it. Semaglutide is an approved prescription medicine, cleared for type 2 diabetes, chronic weight management, cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity, and — as of 2025 — metabolic dysfunction-associated steatohepatitis. Tirzepatide is likewise approved, first for type 2 diabetes in May 2022 and subsequently for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity. Bremelanotide, the approved form of PT-141, was cleared in June 2019 for one narrowly drawn indication in premenopausal women. CJC-1295 and BPC-157 are in a different category entirely. Neither has been approved for human use by any major regulator. Both are sold by research suppliers for laboratory use only. Both are prohibited in sport at all times. And in both cases the published human evidence is limited to a small number of early studies, while the bulk of what circulates as knowledge comes from animal work or from user reports. A name will not always tell a reader which side of that line a compound sits on. But a name plus a naming convention very often will, and that is what the pages here are for. ## How to read the pages that follow Each compound gets its own page, opening with a plain-English summary before the technical detail, and each page ends by returning to the naming question that compound illustrates best. The **[compare page](/compare)** sets the five side by side and distils the whole thing into a reading key — a short list of the patterns a reader can apply to a name encountered anywhere. Every quantitative statement traces to a numbered source in the **[references](/references)**. Where the corpus behind this site does not support a claim, the claim is not made; where the origin of a name is genuinely unrecorded — as with the numeral in BPC-157 — that is said plainly rather than filled in with a plausible story. Community reports appear on each compound page, always labelled as what they are, and never attached to a dose. mybiopeptides sells nothing, prescribes nothing, and recommends no dose to anyone. It reads the literature and reports what is in it. --- mybiopeptides reads the peptide literature by its labels — an independent editorial digest of published research, not a clinic, not a pharmacy, and not a source of dosing advice.